Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

CT
1 program
1
TQC2731 injectionPhase 31 trial
Active Trials
NCT07107256RecruitingEst. Sep 2027
Airway Therapeutics
Airway TherapeuticsGA - Marietta
1 program
Biologic drugsN/A1 trial
Active Trials
NCT06617754Active Not Recruiting3,000Est. Jan 2032

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
Chia Tai TianQing Pharmaceutical GroupTQC2731 injection
Airway TherapeuticsBiologic drugs

Clinical Trials (2)

Total enrollment: 3,000 patients across 2 trials

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

Start: Sep 2025Est. completion: Sep 2027
Phase 3Recruiting

International Severe CRSwNP Registry 2024-2028

Start: Mar 2025Est. completion: Jan 20323,000 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 3,000 patients
2 companies competing in this space